Trial Profile
An Open-Label Phase I/II Study of GSK2110183 in Combination With Carboplatin and Paclitaxel in Subjects With Platinum-Resistant Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Afuresertib (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms AKTRES
- 18 Dec 2018 Results of dose-escalation and expansion study of Afuresertib, published in the Clinical Cancer Research.
- 07 Jun 2016 Results assessing maximum tolerated dose in phase I portion and efficacy in phase II portion of the study presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 22 Dec 2014 Planned number of patients changed from 43 to 60 as reported by ClinicalTrials.gov record.